132 related articles for article (PubMed ID: 15308626)
1. Differential sensitivity of v-Myb and c-Myb to Wnt-1-induced protein degradation.
Kanei-Ishii C; Nomura T; Tanikawa J; Ichikawa-Iwata E; Ishii S
J Biol Chem; 2004 Oct; 279(43):44582-9. PubMed ID: 15308626
[TBL] [Abstract][Full Text] [Related]
2. Wnt-1 signal induces phosphorylation and degradation of c-Myb protein via TAK1, HIPK2, and NLK.
Kanei-Ishii C; Ninomiya-Tsuji J; Tanikawa J; Nomura T; Ishitani T; Kishida S; Kokura K; Kurahashi T; Ichikawa-Iwata E; Kim Y; Matsumoto K; Ishii S
Genes Dev; 2004 Apr; 18(7):816-29. PubMed ID: 15082531
[TBL] [Abstract][Full Text] [Related]
3. Fbxw7 acts as an E3 ubiquitin ligase that targets c-Myb for nemo-like kinase (NLK)-induced degradation.
Kanei-Ishii C; Nomura T; Takagi T; Watanabe N; Nakayama KI; Ishii S
J Biol Chem; 2008 Nov; 283(45):30540-8. PubMed ID: 18765672
[TBL] [Abstract][Full Text] [Related]
4. The Wnt-NLK signaling pathway inhibits A-Myb activity by inhibiting the association with coactivator CBP and methylating histone H3.
Kurahashi T; Nomura T; Kanei-Ishii C; Shinkai Y; Ishii S
Mol Biol Cell; 2005 Oct; 16(10):4705-13. PubMed ID: 16055500
[TBL] [Abstract][Full Text] [Related]
5. Requirement of the co-repressor homeodomain-interacting protein kinase 2 for ski-mediated inhibition of bone morphogenetic protein-induced transcriptional activation.
Harada J; Kokura K; Kanei-Ishii C; Nomura T; Khan MM; Kim Y; Ishii S
J Biol Chem; 2003 Oct; 278(40):38998-9005. PubMed ID: 12874272
[TBL] [Abstract][Full Text] [Related]
6. Wnt activates the Tak1/Nemo-like kinase pathway.
Smit L; Baas A; Kuipers J; Korswagen H; van de Wetering M; Clevers H
J Biol Chem; 2004 Apr; 279(17):17232-40. PubMed ID: 14960582
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation-dependent down-regulation of c-Myb DNA binding is abrogated by a point mutation in the v-myb oncogene.
Andersson KB; Kowenz-Leutz E; Brendeford EM; Tygsett AH; Leutz A; Gabrielsen OS
J Biol Chem; 2003 Feb; 278(6):3816-24. PubMed ID: 12456674
[TBL] [Abstract][Full Text] [Related]
8. c-Myb and v-Myb are differentially phosphorylated by p42mapk in vitro.
Aziz N; Wu J; Dubendorff JW; Lipsick JS; Sturgill TW; Bender TP
Oncogene; 1993 Aug; 8(8):2259-65. PubMed ID: 8336948
[TBL] [Abstract][Full Text] [Related]
9. Nemo-like kinase associated with proliferation and apoptosis by c-Myb degradation in breast cancer.
Huang Y; Jiang Y; Lu W; Zhang Y
PLoS One; 2013; 8(7):e69148. PubMed ID: 23935942
[TBL] [Abstract][Full Text] [Related]
10. Modulation of c-Myb-induced transcription activation by a phosphorylation site near the negative regulatory domain.
Aziz N; Miglarese MR; Hendrickson RC; Shabanowitz J; Sturgill TW; Hunt DF; Bender TP
Proc Natl Acad Sci U S A; 1995 Jul; 92(14):6429-33. PubMed ID: 7604007
[TBL] [Abstract][Full Text] [Related]
11. CBP as a transcriptional coactivator of c-Myb.
Dai P; Akimaru H; Tanaka Y; Hou DX; Yasukawa T; Kanei-Ishii C; Takahashi T; Ishii S
Genes Dev; 1996 Mar; 10(5):528-40. PubMed ID: 8598284
[TBL] [Abstract][Full Text] [Related]
12. Differential regulation of c-Myb-induced transcription activation by a phosphorylation site in the negative regulatory domain.
Miglarese MR; Richardson AF; Aziz N; Bender TP
J Biol Chem; 1996 Sep; 271(37):22697-705. PubMed ID: 8798443
[TBL] [Abstract][Full Text] [Related]
13. Pim-1 phosphorylates the DNA binding domain of c-Myb.
Winn LM; Lei W; Ness SA
Cell Cycle; 2003; 2(3):258-62. PubMed ID: 12734436
[TBL] [Abstract][Full Text] [Related]
14. Histone H3 tail positioning and acetylation by the c-Myb but not the v-Myb DNA-binding SANT domain.
Mo X; Kowenz-Leutz E; Laumonnier Y; Xu H; Leutz A
Genes Dev; 2005 Oct; 19(20):2447-57. PubMed ID: 16195416
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic point mutations in the Myb DNA-binding domain alter the DNA-binding properties of Myb at a physiological target gene.
Ivanova O; Braas D; Klempnauer KH
Nucleic Acids Res; 2007; 35(21):7237-47. PubMed ID: 17959653
[TBL] [Abstract][Full Text] [Related]
16. Enhanced proliferative potential of hematopoietic cells expressing degradation-resistant c-Myb mutants.
Corradini F; Cesi V; Bartella V; Pani E; Bussolari R; Candini O; Calabretta B
J Biol Chem; 2005 Aug; 280(34):30254-62. PubMed ID: 15927960
[TBL] [Abstract][Full Text] [Related]
17. The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF.
Ishitani T; Ninomiya-Tsuji J; Nagai S; Nishita M; Meneghini M; Barker N; Waterman M; Bowerman B; Clevers H; Shibuya H; Matsumoto K
Nature; 1999 Jun; 399(6738):798-802. PubMed ID: 10391247
[TBL] [Abstract][Full Text] [Related]
18. c-Myb-induced trans-activation mediated by heat shock elements without sequence-specific DNA binding of c-Myb.
Kanei-Ishii C; Yasukawa T; Morimoto RI; Ishii S
J Biol Chem; 1994 Jun; 269(22):15768-75. PubMed ID: 8195231
[TBL] [Abstract][Full Text] [Related]
19. Homeodomain-interacting protein kinase 2 (HIPK2) targets beta-catenin for phosphorylation and proteasomal degradation.
Kim EA; Kim JE; Sung KS; Choi DW; Lee BJ; Choi CY
Biochem Biophys Res Commun; 2010 Apr; 394(4):966-71. PubMed ID: 20307497
[TBL] [Abstract][Full Text] [Related]
20. HIPK1 interacts with c-Myb and modulates its activity through phosphorylation.
Matre V; Nordgård O; Alm-Kristiansen AH; Ledsaak M; Gabrielsen OS
Biochem Biophys Res Commun; 2009 Oct; 388(1):150-4. PubMed ID: 19646965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
